Type II diabetes is caused by a failure of the pancreatic b-cells to compensate for insulin resistance leading to hyperglycaemia. There is evidence for an essential role of an increased b-cell apoptosis in type II diabetes. High glucose concentrations induce IL-1b production in human b-cells, Fas expression and concomitant apoptosis owing to a constitutive expression of FasL. FASL and FAS map to loci linked to type II diabetes and estimates of insulin resistance, respectively. We have tested two functional promoter polymorphisms, FAS-670 G4A and FASL-844C4T as well as a microsatellite in the 3 0 UTR of FASL for association to type II diabetes in 549 type II diabetic patients and 525 normal-glucose-tolerant (NGT) control subjects. Furthermore, we have tested these polymorphisms for association to estimates of b-cell function and insulin resistance in NGT subjects. We found significant association to type II diabetes for the allele distribution of the FASL microsatellite (P-value 0.02, Bonferroni corrected). The FAS-670G4A was associated with homeostasis model assessment insulin resistance index and body mass index (P-values 0.02 and 0.02). We conclude that polymorphisms of FASL and FAS associate with type II diabetes and estimates of insulin resistance in Danish white subjects.
Introduction
Type II diabetes is caused by a failure of the b-cells to maintain normoglycaemia when insulin resistance is present. 1 Although increased caloric intake and reduced physical activity are major environmental risk factors responsible for its rising prevalence, type II diabetes is considered a complex heritable disease. The recurrence risk (l) is 10 in monozygotic twins 2 and 3.5 in firstdegree relatives. 3 The life-time risk for the development of type II diabetes in non-diabetic offspring, siblings and dizygotic twins is around 40%. 4 Multiple gene variations of modest effect are thought to contribute to the overall susceptibility to type II diabetes. 5 The ability to secrete adequate amounts of insulin depends on pancreatic b-cell function and b-cell mass. Increasing evidence points to a central role for a decline in b-cell mass owing to an increased b-cell apoptosis in the pathophysiology of type II diabetes. 6, 7 Chronic elevation of glucose concentration impairs b-cell function. Elevated circulating levels of proinflammatory cytokines are present in patients with recent onset of type II diabetes. 8 In human b-cells, elevated glucose concentrations upregulate Fas, activate caspase-8 and -3 and may lead to apoptosis. 9 The corresponding Fas ligand is constitutively expressed in human islets. 10 Genome scans in type II diabetes have identified several regions with evidence for linkage, among these a locus on chromosome 1q24-25, where the highest LOD score is obtained for the marker D1S218 adjacent to (within 1.9 Mbp) the Fas ligand gene, FASL. This locus was found to interact with a locus on chromosome 10q23-24 harbouring the Fas gene, FAS.
11 Phenotypic variability among individuals at risk for developing overt diabetes is observed and stratifying by different traits may reduce heterogeneity and aid in identifying responsible gene polymorphisms. In a genome scan performed in 719 sib pairs with type II diabetes, an ordered-subset analysis based on families with high or low diabetes related quantitative traits identified linkage to 10q23-24 at 114.5 cM for the lowest IR 1 (fasting-insulin/fastingglucose ratio). 12 FAS maps in the near vicinity of this locus at 113 cM.
Fas belongs to the death receptor (DR) family (Figure 1 ), which transduce either apoptotic or survival signals. Binding of FasL to Fas recruits FADD and triggers the formation of the death-inducing signalling complex (DISC), activating caspase-8. In type I cells, caspase-8 directly activates caspase-3, whereas in type II cells the mitochondrial pathway releases cytochrome c, the apoptosome is formed and caspase-3 is activated. Both pathways lead to apoptosis. 13, 14 However, Fas seems to be not only an apoptosis-inducing receptor, but rather a key regulator of cell cycle. Depending on the presence of intracellular cofactors, such as FLICE (caspase-8) inhibitory protein (FLIP), Fas signalling can also lead to proliferation. FLICE (caspase-8) inhibitory protein is constitutively expressed in human b-cells but is downregulated by high glucose concentrations. 15 We have earlier identified several polymorphisms in the human Fas and FasL genes. 16, 17 We have further characterized the functional properties of promoter polymorphisms and haplotypes in FAS as well as FASL and demonstrated that the FAS-670G and the FASL-844C-478A lead to higher promoter activities. 18 As the Fas/ FasL system may be important in glucose-induced b-cell apoptosis in vitro and in certain animal models of type II diabetes, 19 the aim of this study was to test functional polymorphisms in FAS and FASL as well as an FASL microsatellite for association to type II diabetes and to quantitative metabolic traits.
Results
Case-control study Genotype distributions were in Hardy-Weinberg equilibrium for the FASL-844C4T, FAS-670G4A polymorphisms and the FASL microsatellite in glucose-tolerant subjects. As can be seen from Table 1 , we found no significant difference in genotype distribution between type II diabetic patients and glucose-tolerant subjects for the FAS-670G4A and FASL-844C4T polymorphisms (P-values 0.16 and 0.4) or in the allele distribution for these two polymorphisms (P-values 0.3 and 0.4). The alleles of the FASL microsatellite ranged from 14 to 19 repeats. Of these the 16-allele and the 17-allele were by far the most frequent, making up 76 and 20% of the alleles, respectively. We therefore combined the 14-, 15-, 18-and 19-alleles and denoted them as allele X. We then established genotypes from the 16-, 17-and X-alleles and analyzed these for association to type II diabetes. We found a significant association to type II diabetes for the alleles of the FASL microsatellite (P-value 0.009, w 2 2df ¼ 9.39; Bonferroni corrected P-value 0.02), see Table 1 .
Genotype-quantitative trait study As can been seen from Table 2 , there was no significant association with estimates of pancreatic b-cell function or estimates of insulin resistance apart from fasting serum C-peptide (P-value 0.04) in normal-glucose-tolerant (NGT) subjects for any of the genotypes of the FASL microsatellite. We found an association of the FAS-670G4A polymorphism (Table 3 ) with the following estimates of insulin resistance: homeostasis model assessment (HOMA) insulin resistance index (P-value 0.02), fasting serum insulin level (P-value 0.02) and IR 1 (P-value 0.04). FAS-670G4A was also associated to body mass index (BMI) (P-value 0.02). The FAS-670GG genotype was associated with the lowest fasting serum insulin level, IR 1 and HOMA IR, followed by the AA and GA genotypes. Carriers of the FAS-670GG genotype had the highest BMI, followed by carriers of the GA and AA genotypes. The FASL-844C4T was not associated with any of the subphenotypic traits (data not shown). The genotypes of the FAS-670G4A and FASL-844C4T were combined in the NGT subjects and tested for association to the same intermediate metabolic traits. There was, however, no association to any of the examined quantitative traits (data not shown).
Discussion
In this study, we demonstrate for the first time an association between a polymorphism in the apoptosisinducing ligand gene, FASL, and type II diabetes, where the allele distribution of the FASL microsatellite in the 3 0 UTR of the gene is associated with type II diabetes. In glucose-tolerant subjects, the genotypes of the functional FAS-670G4A promoter polymorphism were associated with estimates of insulin resistance.
The tested polymorphisms in the FAS and FASL promoters were selected because they are functional affecting transcription factor-binding sites and promoter activity. The FAS-670G4A affects signal transducer and activator of transcription (STAT)1 binding leading to altered promoter activity. FAS-670A leads to a significantly lower promoter activity of FAS. 18 We thus expected this allele to lead to a lower transcription rate and possibly lower Fas cell surface expression. However, Sun et al. 20 have recently shown that the FAS-670A variant is expressed more highly on ex vivo activated T cells.The FASL-844C4T polymorphism affects the binding site of the transcription factor CAAT/enhancerbinding protein b, EBPb, 21 as well as the activity of the FASL promoter. 18 As there is strong linkage disequilibrium (LD) between the FASL-844 and FASL-478 as well as a low frequency (0.1) of the rarer FASL-478T allele, the FASL-478 has not been tested in this study.
The microsatellite is a dinucleotide repeat (GT) in 3 0 UTR of FASL very close to exon 4 and might have an effect upon mRNA stability. The HapMap shows strong LD between polymorphisms in FAS, whereas there is only weak LD between the FASL-844C4T and microsatellite. 18 We therefore assumed that testing the FASL microsatellite in addition to the functional FASL-844C4T would provide additional information regarding the genetic association of FASL in type II diabetes.
We found a significant association (P-value 0.02, Bonferroni corrected) of the allele distribution of the FASL microsatellite to type II diabetes, but no significant 16 and similarly in European American Systemic lupus erythematosus patients the pair-wise LD was 0.410 (À1.0-1.0). 18 We found association of the FAS-670A with fasting serum insulin level, IR 1 and HOMA-IR, all estimates of insulin resistance. Experimental evidence in humans and rodents points to a role for IL-1b induced Fas expression in the increased b-cell apoptosis observed in chronic exposure to high glucose, 15, 19 although this issue is debated. 22 We thus suspected that the functional polymorphisms in FAS and FASL leading to increased Fas/ FasL expression would primarily have an effect upon b-cell apoptosis and concomitantly b-cell mass and function. Since linkage studies in subgroups more homogenous for diabetes-related traits found linkage to a region only 1.5 cM upstream of FAS for the lowest IR 1 on chromosome 10q23-24, 12 we included IR 1 as a phenotypic trait.
Fas plays a role in non-apoptotic responses such as cell proliferation and inflammation, as well as in apoptosis. How can Fas play a role in insulin resistance? The c-Jun N-terminal kinase (JNK) signalling pathway is activated by Fas in an FADD/caspase-8-dependent as well as a caspase-independent pathway 23 ( Figure 1 ). The JNK pathway plays a role in the progression of insulin resistance. 24 In mouse models of obesity, JNK activity is elevated in insulin target tissues, such as liver, fat and muscle. The JNK À/À mice on a high-fat diet have reduced body weight, lower blood glucose and lower plasma insulin levels compared to control JNK þ / þ mice, which are obese, hyperglycaemic and hyperinsulinaemic on a similar diet. 25 Activation of the JNK pathway inhibits the insulin signalling cascade by phosphorylating the critical Ser 307 residue in the insulin receptor substrate 1 (IRS-1). 26 Inhibition of JNK in C57BL/Ksj-db/db obese diabetic mice reduces hyperglycaemia and this correlates with reduced phosporylation of Ser 307 in IRS-1. 27 As can be seen from Table 3 , carriers of the FAS-670AA genotype are more insulin resistant than carriers of the FAS-670GG genotype in spite of a lower BMI. The association of FAS-670A to insulin resistance could be explained by higher Fas cell surface expression, activation of the JNK pathway and inhibition of the insulin signalling cascade, see Figure 1 .
To 11 LOD 1.98. We conclude that in the examined Danish study population, the FASL microsatellite is associated with type II diabetes and the functional FAS-670G4A promoter polymorphism may be associated with insulin resistance. However, our results need confirmation in larger case-control studies.
Subjects, materials and methods

Subjects
The case-control study of the FAS -670G4A (dbSNP rs 1800682), FASL-844C4T (dbSNP rs 763110) and FASL microsatellite (dbSNP rs10640513) was performed in 549 (324M/225F) unrelated type II diabetic patients recruited from the outpatient clinic at Steno Diabetes Center and in a control group comprising 231 (113M/118F) unrelated subjects sampled during 1994-1997 at Steno Diabetes Center and 294 (134M/160F) subjects sampled from the Research Centre for Prevention and Health, Glostrup. 31 The control subjects were traced randomly in the Danish Central Population Register and were living in the same area of Copenhagen as the type II diabetic patients. Only subjects who were normoglycaemic and glucose-tolerant (NGT) following an oral glucose tolerance test were included as control individuals in this protocol. In the group of diabetic patients, mean age was 61711 years, age at clinical diagnosis 55711 years, BMI 29.075.2 kg/m 2 and HbA 1 c 8.071.6%. The patients were treated with diet alone (27%), with oral hypoglycaemic agent (58%) or with insulin alone or in combination with oral hypoglycaemic agent (15%). In the group of NGT subjects, mean age was 57710 years and BMI 25.873.7 kg/m 2 . Diabetes was diagnosed according to World Health Organization criteria. 32 All control subjects underwent a standard 75-g oral glucose tolerance test (OGTT). All participants were Danish white subjects by self-report. Informed written consent was obtained from all subjects before participation. The study was approved by the Ethics Committee of Copenhagen and was in accordance with the principles of the Declaration of Helsinki II.
Biochemical assays
Blood samples were drawn after a 12-h overnight fast and plasma glucose, serum-specific insulin levels, serum C-peptide and HbA 1 c were measured using Steno Diabetes Center routine methods. The genotype-quantitative trait studies were performed in the 525 normal glucose-tolerant subjects for the FAS -670G4A, FASL-844C4T and FASL microsatellite. Some subjects were not included in the analyses because of missing genotype data and only subjects with genotype data are presented in the tables. The genotyping success rates ranged from 95 to 100%. The genotyping error rate was less than 1%. Calculations for IR 1 , insulinogenic index-insulin and HOMA-IR were as follows: IR 1 (fasting-insulin/fasting-glucose), Insulinogenic index-insulin ((insulin 30 minÀfasting-insulin)/ glucose 30 min) and HOMA-IR ((fasting-glucose Â fasting-insulin)/22.5). Homeostasis Model Assessment is an estimate of insulin resistance, 33 and the insulinogenic index-insulin is a measurement of the early insulin response. 34 
Methods
Genotyping
We genotyped all subjects for a total of three SNPs in FAS and FASL: Two functional promoter polymorphisms, FAS-670 G4A and FASL-844 C4T, affecting the binding sites of STAT1 and EBPb, respectively, as well as an FASL (GT)n microsatellite in the 3 0 UTR of FASL. The genotyping of FAS-670 G4A and the FASL (GT)n microsatellite is described in detail by Nolsoe et al. [16] [17] [18] Briefly, using 3 ng of DNA per reaction, we genotyped the À670 G4A in FAS and the À844 C4T in FASL by PCR-based Restriction Fragment Length Polymorphisms assays with Mva1 and BsrD1 as restriction enzymes for FAS À670 G4A and FASL À844 C4T, respectively. Primer sequences for the genotyping of the FASL-844 C4T yielding a PCR product of 449 base pairs were: forward primer 5 0 AACATAGAAAGTCCCCATCTG-3 0 , reverse primer 5 0 GGCCAGAGAAGTCACTCC-3 0 . The PCR cycling conditions were 951C (3 min) for one cycle followed by 951C (30 s), 521C (40 s) and 721C (40 s) for 38 cycles. A final cycle of 721C for 3 min completed the reaction. In total, 10 ml of the amplified PCR product was digested with 5 U of BsrD1 overnight at 371C in a 20 ml final reaction volume using 2 ml of the accompanying reaction buffer. The digested products were resolved on a 2% agarose gel stained with ethidium bromide and visualized using UV transillumination.
Using biotinylated primers, we typed the FASL (GT)n microsatellite in the 3 0 UTR of FASL by PCR of genomic DNA followed by PAGE, blotting and visualization utilizing a streptavidin-peroxidase catalyzed ECL reaction. To avoid genotyping errors, sequenced controls of each genotype were included, and genotypes were determined independently by two observers, before being entered into the datasheet by two different staff members. Samples with indeterminate genotype were regenotyped twice, and only samples with reproducible genotypes were included in the datasheet.
Statistical analysis
Fisher's exact test was applied to examine differences in allele frequencies and genotype distributions between type II diabetic and NGT subjects. Phenotypic differences between the genotype groups among NGT subjects were tested with a general linear model including gender and genotype as fixed factors and age and BMI as covariate factors. For the genotype-quantitative trait studies, a normal distribution of the residuals was verified and if appropriate, logarithmically transformed. The following quantitative traits required transformation: s-insulin, IR1, insulinogenic index-insulin, s-C-peptide and HOMA insulin resistance index. A P-value of less than 0.05 was considered significant. All analyses were carried out using Statistical Package for Social Sciences (SPSS) for Windows, version 12.0 (http://www.spss.com).
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